Eddie Hickman
Stock Analyst at Guggenheim
(3.75)
# 699
Out of 5,163 analysts
21
Total ratings
80%
Success rate
30.95%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eddie Hickman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TARS Tarsus Pharmaceuticals | Maintains: Buy | $87 → $90 | $67.96 | +32.43% | 10 | Feb 25, 2026 | |
| PMN ProMIS Neurosciences | Maintains: Buy | $125 → $35 | $18.15 | +92.84% | 4 | Feb 6, 2026 | |
| ATAI AtaiBeckley | Initiates: Buy | $11 | $3.69 | +198.10% | 1 | Jan 20, 2026 | |
| OTLK Outlook Therapeutics | Downgrades: Neutral | n/a | $0.39 | - | 4 | Aug 29, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Buy | $20 → $22 | $9.98 | +120.44% | 1 | Mar 13, 2025 | |
| GHRS GH Research | Initiates: Buy | $32 | $14.95 | +114.05% | 1 | Mar 13, 2025 |
Tarsus Pharmaceuticals
Feb 25, 2026
Maintains: Buy
Price Target: $87 → $90
Current: $67.96
Upside: +32.43%
ProMIS Neurosciences
Feb 6, 2026
Maintains: Buy
Price Target: $125 → $35
Current: $18.15
Upside: +92.84%
AtaiBeckley
Jan 20, 2026
Initiates: Buy
Price Target: $11
Current: $3.69
Upside: +198.10%
Outlook Therapeutics
Aug 29, 2025
Downgrades: Neutral
Price Target: n/a
Current: $0.39
Upside: -
Zevra Therapeutics
Mar 13, 2025
Maintains: Buy
Price Target: $20 → $22
Current: $9.98
Upside: +120.44%
GH Research
Mar 13, 2025
Initiates: Buy
Price Target: $32
Current: $14.95
Upside: +114.05%